IGF-2/IGF-1R Inhibition Shows Promise in Esophageal Cancer

Get Permission

In a study reported in Clinical Cancer Research, Li and colleagues found that overexpression of Id1 protein resulted in insulin-like growth factor (IGF)-2 production, which, in turn, resulted in esophageal cancer cell proliferation, survival, and invasion via autocrine activation of AKT.

Overexpression of IGF-2 was identified in 60% of tumor samples from patients with esophageal cancer and was associated with upregulation of Id1 and phosphorylated AKT. In Id1-overexpressing xenografts, secreted IGF-2 promoted growth of distant esophageal tumors and metastasis of circulating cancer cells.

Intratumoral injection of IGF-2 antibody and intraperitoneal injection of the IGF-1 receptor (IGF-1R) antibody cixutumumab resulted in significant suppression of tumor growth and metastasis in mice. Further, cixutumumab increased the sensitivity of tumor xenografts to fluorouracil and cisplatin.

The investigators concluded, “The Id1–[IGF-2–IGF-1R]–AKT signaling cascade plays an important role in esophageal cancer progression. Blockade of [IGF-2/IGF1R] signaling has therapeutic potential in the management of esophageal cancer.” ■

Li B, et al: Clin Cancer Res 20:2651-2662, 2014.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.